Aurinia Pharmaceuticals Inc. Subsidiaries
Every subsidiary the company listed in Exhibit 21 of its annual reports, newest list first (6 lists). Names and jurisdictions are as filed.
- 2026-02-26: Subsidiary Aurinia Pharma U.S., Inc.; Jurisdiction Delaware.
- 2025-02-27: Subsidiary Aurinia Pharma U.S., Inc.; Jurisdiction Delaware.
- 2025-02-27: Subsidiary Aurinia Pharma Limited; Jurisdiction United Kingdom.
- 2024-02-15: Subsidiary Aurinia Pharma U.S., Inc.; Jurisdiction Delaware.
| Annual report filed | Subsidiary | Jurisdiction |
|---|---|---|
| 2026-02-26 | Aurinia Pharma U.S., Inc. | Delaware |
| 2025-02-27 | Aurinia Pharma U.S., Inc. | Delaware |
| 2025-02-27 | Aurinia Pharma Limited | United Kingdom |
| 2024-02-15 | Aurinia Pharma U.S., Inc. | Delaware |
| 2024-02-15 | Aurinia Pharma Limited | United Kingdom |
| 2023-02-28 | Aurinia Pharma U.S., Inc. | Delaware |
| 2023-02-28 | Aurinia Pharma Limited | United Kingdom |
| 2022-02-28 | Aurinia Pharma U.S., Inc. | Delaware |
| 2022-02-28 | Aurinia Pharma Limited | United Kingdom |
| 2021-02-24 | Aurinia Pharma U.S. Inc. | Delaware |
| 2021-02-24 | Aurinia Pharma Limited | United Kingdom |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |